Most recent update: Tuesday, September 25, 2018 - 16:47

Bariatric News - Cookies & privacy policy

You are here

Obalon distribution deal

Obalon agrees South Korean deal for OGB System

Obalon has granted PacificPharma exclusive rights to market and distribute Obalon’s device for weight loss in South Korea, subject to regulatory approval

Obalon Therapeutics has received a strategic investment from AMOREPACIFIC Ventures and entered into an exclusive international distributorship agreement with PacificPharma, an AMOREPACIFIC Group subsidiary, for its non-surgical device for weight loss, the Obalon Gastric Balloon (OGB) System. Obalon has granted PacificPharma exclusive rights to market and distribute Obalon’s device for weight loss in South Korea, subject to regulatory approval of the device by the Korea Food and Drug Administration (KFDA).

“We are very pleased to have the opportunity to work with PacificPharma to commercialize our technology for weight loss in Korea,” said Andy Rasdal, Obalon’s Chief Executive Officer.  “We believe PacificPharma’s proven capabilities and expertise make them an ideal partner for Obalon.”

Obalon is developing a novel non-surgical, fully-reversible device for weight loss. The OGB system consists of a capsule containing a balloon that is swallowed and then remotely inflated. The balloon is intended to occupy space in the stomach to create a feeling of fullness to help people eat less. Additional balloons can be swallowed and inflated during the treatment period as indicated for weight loss. At the end of the treatment period, the balloons are removed.

“It is a great pleasure to establish this collaboration with Obalon,” said Won-Joon Ahn, PacificPharma’s Chief Executive Officer. “We believe Obalon’s highly differentiated novel non-surgical device will be an important treatment option for patients in Korea and a solution for the unmet medical need for weight loss.”

Obalon received IDE approval from the FDA and is enrolling its first US feasibility clinical trial evaluating the safety and efficacy of the device. The company has completed four clinical trials outside the US.

The company has obtained CE Mark Registration for the Obalon Gastric Balloon System and has commenced initial commercial sales in the EU.  In the US, the device is not commercially available and is only being studied in clinical trials as an investigational device.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.